Email
Print
Advanced Therapy Medicinal Products Market - Forecast(2024 - 2030)
Advanced Therapy Medicinal Products Market Overview
The Advanced Therapy Medicinal Products market size was estimated at $8.34 billion in 2020, growing at a CAGR of 13.5% during the forecast period 2021-2026. Advanced therapy medical products (ATMPs) are a class of novel and sophisticated biological products that, under most circumstances, require substantial and time-consuming preclinical and clinical testing. These medical devices are revolutionary treatments that rely on high-quality treatment, extensive cell treatment, and tissue-constructed products. Gene therapy and somatic cell therapy account for the maximum number of products, while Combined Advanced Therapies that can contain one or more medical devices are a growing type. These products lead to a therapeutic, prophylactic, or diagnostic effect. ATMPs can cure diseases by treating the underlying cause rather than the symptoms. As a result, ATMPs assist in delivering revolutionary benefits that are not available with traditional treatments. These factors are predicted to drive the Advanced Therapy Medicinal Products market During the forecast period 2021-2026.
Report Coverage
Key Takeaways
- North America dominated the Advanced Therapy Medicinal Products Market in 2020 owing to the rise in cancer and cardiovascular patients and the substantial improvement in healthcare infrastructure.
- Increasing technological advancement in Advanced Therapy Medicinal Products is set to aid the market growth of the Advanced Therapy Medicinal Products Market report.
- The Advanced Therapy Medicinal Products Market report will provide a detailed analysis of the Strength, Weaknesses, and Opportunities of the prominent players operating in the Market.
Advanced Therapy Medicinal Products Market Revenue Share, By Geography, 2020(%)
For more details on this report - Request for Sample
Advanced Therapy Medicinal Products Market Segment Analysis – By Product
Based on product, the market for Advanced Therapy Medicinal Products is
segmented into Gene Therapy, Somatic Cell Therapy, Tissue-Engineered Therapies, and Combined Advanced Therapies. The somatic Cell Therapy segment held the largest share in the Advanced
Therapy Medicinal Products market in 2020. It is also estimated to register a higher CAGR
of 16.6% during the forecast period 2021-2026 owing to rising technological
advancement and application to treat malignancies, autoimmune diseases, urinary
difficulties, and infectious diseases, as well as to restore damaged cartilage
in joints, heal spinal cord injuries, strengthen a weakened immune system, and
assist individuals with neurological abnormalities.
Advanced Therapy Medicinal Products Market Segment Analysis – By Indication
On the basis of indication, the market for Advanced Therapy Medicinal
Products is categorized in Oncology, Cardiovascular
Diseases, Immunological Disorder, Neuro-Neuromuscular Diseases, and Others. The oncology segment held the largest share in the Advanced Therapy Medicinal Products
market in 2020. Owing to the
growing number of cancer cases, the oncology segment is also estimated to
register a higher CAGR of 17.3% during the forecast period 2021-2026. Advance therapy
medicines are a relatively new type of precision medicine that boosts the
immune system's ability to combat cancer cells that the body has failed to
perceive as a threat. For instance, Kymriah is a highly individualized cancer
treatment that uses CAR T-cell therapy to extract a person's cells, reengineer
them, and then reintroduce them into their bodies to kill cancer cells.
Advanced Therapy Medicinal Products Market Segment Analysis – By Geography
North America
dominated the Advanced Therapy Medicinal Products market with a significant
share of 44% in 2020. This is attributed to the rise in cancer and
cardiovascular patients along with the substantial improvement in healthcare
infrastructure in this region. Additionally, growing technological advancement in advanced therapy
medicinal products, owing to the investment from the top players for the
research and development in this region, is contributing to the growth of the
market in this region.
However, Asia
Pacific is estimated to grow at a higher CAGR during the forecast period
2021-2026, owing to rising spending capacity in healthcare in developing
countries in this region. Moreover, increasing awareness of the benefits of advanced therapy medicinal products among the physicians
and general people in the area is augmenting the market growth in this region.
Advanced Therapy Medicinal Products Market Drivers
Increasing prevalence of chronic diseases that uses Advance therapy medical products
The rising prevalence of cancer,
cardiovascular, musculoskeletal, immune system/inflammation, neurology, and
many other chronic diseases demand advanced therapy products. According to a report published by Globocan
2020, the Global cancer burden predictions have increased to 19.3 million cases and
10 million cancer deaths in 2020. Cardiovascular diseases (CVDs) are the
leading cause of mortality worldwide, killing an estimated 17.9 million people
each year. In the United States alone, 30.3 million individuals (12.1%) have
been diagnosed with CVD. The high prevalence of chronic disease coupled with
the increasing investment by the key companies is driving the market growth.
Rising R&D and scientific advancement in the field of Advance therapies.
Since 2017, groundbreaking scientific advances have resulted in three
CAR T approvals for Acute lymphoblastic leukemia and Diffuse Large B-Cell
Lymphoma. CAR T-cell treatments that have been approved are presently used to
treat a few numbers of relapsed or refractory liquid tumors that afflict less
than 5% of cancer patients. While early research focused on a small number of
targets, such as CD19, today's clinical trials cover a broader range of targets
and tumor types. Clinical data has been the driving force behind the increased
industry interest in medicines. As a result of advanced research and
development efforts, clinical studies for investigational cell therapies have
exploded in recent years, with over 1000 trials underway.
Advanced Therapy Medicinal Products Market Challenges
Complexity in the manufacturing and supply chain functions of the Advanced Therapy Medicinal products.
The one-batch, one-patient paradigm shift has resulted in complex and
costly production and supply chains for all CAR T-cell medicines on the market
and around 75% of clinical assets. Autologous CAR T manufacturing is now highly
centralized, with limited economies of scale. This strategy is more analogous
to modular clean rooms and lab-like facilities than to manufacturing plants. A
scarcity of manufacturing slots for the CAR T cell or the required viral vector
is frequently noted as a significant barrier among CAR T cell therapy centers.
Furthermore, a sophisticated cold chain is needed to transport apheresed and
produced cells between manufacturing sites and hospitals. These manufacturing
issues have resulted in an extraordinarily high cost of products sold with a
large fixed percentage, a reluctance to use CAR T beyond end-of-line patients,
and patient drop-offs throughout the treatment process.
Advanced Therapy Medicinal Products Market Landscape
Product
launches, mergers and acquisitions, joint ventures, and R&D activities are
key strategies adopted by players in the Advanced Therapy Medicinal Products
Market. In 2020, the Advanced Therapy Medicinal Products Market share was
consolidated by the top ten players present in the market. The Advanced Therapy
Medicinal Products Market, the top 10 companies, are
- Celgene Corporation
- Pfizer
- Spark Therapeutics, Inc.
- Bluebird Bio, Inc.
- Novartis AG
- UniQure N.V.
- Gilead Lifesciences, Inc.
- Kolon TissueGene, Inc.
- BioMarin Pharmaceutical.
- Kite Pharma
Advanced Therapy Medicinal Products Market Development:
- In March 2021, Bristol Myers Squibb received FDA clearance for Abecma, a cell-based gene therapy medicinal product designed for treating patients with multiple Myeloma, in partnership with bluebird bio.
- In January 2021, FUJIFILM Diosynth Biotechnologies spent USD 40 million on a new process research and manufacturing facility for innovative medicines and viral vectors, thereby company the companies capacity.
- In August 2019, Pfizer spent $500 million expanding its gene therapy operations in North Carolina, the latest significant pharma investment in burgeoning technology. This expansion will enhance the company's growth in Advanced Therapy Medicinal Products.